Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

February 06, 2006 09:31 ET

Swiss Medica Launches Distribution of Products into U.S. Healthcare Industry

TORONTO, ONTARIO--(CCNMatthews - Feb. 6, 2006) - Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce a U.S. healthcare industry distribution deal with North American Physicians, Inc., ("NAPI") of Boca Raton, Florida. NAPI will distribute all three of Swiss Medica's products (O24 Pain Neutralizer, O24 Fibromyalgia and PMS Escape) into the healthcare community including licensed dispensing physician offices, physician kiosks, pain management clinics, hospitals, therapy centers, hospital pharmacies, and chiropractor and podiatry clinics. The sampling and sale of products will be by healthcare professionals to patients in medical settings, experiencing either acute or chronic pain afflictions as well as mood instability.

NAPI has already started sampling, distributing, and selling all three of Swiss Medica's products into Florida-based physician offices and hospital pharmacies. In addition, NAPI will be establishing freestanding kiosks in medical buildings, professional plazas, and general retail environments to solely sell Swiss Medica products. NAPI consists of multiple physician shareholders.

Swiss Medica's Chief Executive Officer, Raghu Kilambi noted, "As Swiss Medica's elite products are patented, clinically and medically tested and offer quick efficacy for patients, the strategic partnership with NAPI allows us to leverage those advantages over traditional OTC products with the medical community. The feedback to date on our products from the medical community and their patients has been impressive".

Dr. Bob Maurer noted "that all those who try the product have experienced great results". Dr. Maurer is the Former President of the American Osteopathic Association, a professional licencing physician organization with over 50,000 members, in addition to a current member of the Board of Directors of the American Ospeothatic College of Rheumatology.

About Swiss Medica, Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at, and

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit, for ordering details and store locators for the nearest pharmacy.

Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit, for ordering details and store locators for the nearest retailer.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to acceptance of Swiss Medica's products in Canada, the United States and other countries, risks related to international sales and purchases and potential foreign currency exchange fluctuations, acceptance of Swiss Medica's products, increased levels of competition, , dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information